Sysmex’s CN-Series analyzers and CN-9000 automation platform illustrate broader shifts in hemostasis testing, including workflow integration, throughput, and quality control.
A peer-reviewed economic analysis challenges the assumption that erythrocyte sedimentation rate and C-reactive protein tests are interchangeable, finding that combined testing reduces misdiagnoses and lowers overall costs.
The BiliSeq molecular test detected bile duct cancer in 82% of cases—compared to 44% with standard pathology—according to a six-year, multi-institutional study.
The integration gives more than 4,700 oncology providers across 1,600-plus community cancer care centers direct access to order and receive results from multiple precision oncology tests within a single clinical workflow.
Caris Life Sciences has launched Caris ChromoSeq, a whole genome and transcriptome sequencing assay for myeloid malignancies, designed to consolidate multiple tests into a single workflow with a seven-day turnaround.
